C-Bridge Capital
C-Bridge Capital (CBC Group) is a healthcare-focused private equity firm managing RMB-denominated M&A funds across Asia, with a 10 billion yuan flagship fund targeting biomedicine, medical devices, and consumer healthcare.
- Company typePrivate
- Founded2022
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
C-Bridge Capital firmographics
Firmographics- Name
- C-Bridge Capital
- Legal name
- CBC Group
- Website
- https://cbridgecap.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- C-Bridge Capital (CBC Group) is a healthcare-focused private equity firm managing RMB-denominated M&A funds across Asia, with a 10 billion yuan flagship fund targeting biomedicine, medical devices, and consumer healthcare.
- Ownership category
- akta.pro rank
C-Bridge Capital industry classification
Industry- Product category
- Healthcare Private Equity
- NAICS
- Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (52599)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Private Equity Buyout Fund-of-Funds (FSANAGAD)
- akta.pro secondary industry
- Corporate Finance & Capital Advisory (BPAHADAB)
Keywords
Where C-Bridge Capital is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
C-Bridge Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Fund Management: Generates revenue through management fees and carried interest from the RMB healthcare M&A fund. The fund targets 10 billion yuan with an initial close of over 7 billion yuan from institutional investors.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels2 records
C-Bridge Capital product offering
Product offeringCore offering
C-Bridge Capital is a healthcare-focused Chinese principal investment firm that raises and deploys capital through dedicated private equity vehicles, primarily the RMB Healthcare M&A Fund (target size 10 billion yuan, first close over 7 billion yuan). The fund is co-managed with Beijing Shunxi Fund and anchored by Beijing State-owned Assets Management Co., Ltd. and Beijing Yizhuang International Biomedical Investment Management Co., Ltd. The firm invests in and supports portfolio companies in the biopharmaceutical sector, including Everest Medicines and Hugel.
Differentiator
Problem solved
Functional benefit
Products and services
- RMB Healthcare M&A Fund
Companies that use C-Bridge Capital
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles2 records
C-Bridge Capital technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
C-Bridge Capital partnerships and signals
Strategic signalScale indicators2 records
C-Bridge Capital competitors and assessment
Company assessmentDirect peers
- Hillhouse Capital: Asia-focused alternative asset manager with significant healthcare and life sciences exposure across buyouts, growth, and venture. Directly comparable to C-Bridge as a healthcare-specialist investor pursuing platform M&A and integration in China and broader Asia.
- Boyu Capital: Asia-focused private equity firm with active healthcare and biotech practice and substantial Chinese LP base. Comparable to C-Bridge in sector specialization, large RMB-denominated fund vehicles, and use of M&A to build healthcare platforms.
- Vivo Capital: Healthcare-dedicated private equity firm with strong Asia and U.S. franchise investing across pharma, devices, and consumer health. Directly comparable to C-Bridge's healthcare-exclusive mandate, M&A integration playbook, and cross-border deal execution.
- OrbiMed: Dedicated healthcare investment platform operating across private equity, growth, and royalty/credit strategies globally with significant China exposure. Closely comparable to C-Bridge in pure-play healthcare focus and sub-sector coverage spanning biotech, devices, and consumer health.
- Lakeside Capital (Lake Bleu Capital): Hong Kong-based healthcare-focused public and private equity investor with deep China healthcare exposure. Comparable to C-Bridge in healthcare-only mandate and RMB/cross-border execution capability, though typically at smaller scale.
Broad incumbents
- Hopu Investments: Large China-rooted alternative asset manager with significant healthcare investments across buyouts and growth equity. Comparable to C-Bridge in operating model and access to state-affiliated capital, but with a broader sector mandate.
- Bain Capital Asia: Global private equity firm with a dedicated Asia healthcare practice executing control buyouts and growth investments. Comparable to C-Bridge in M&A execution and cross-border healthcare deal flow, but operates as part of a broader multi-strategy platform.
- Warburg Pincus: Global growth investor with long-standing China healthcare franchise investing in pharma, devices, and services. Comparable in cross-border healthcare deal execution and Asia platform building, but with broader sector exposure than C-Bridge.
- Eight Roads Ventures: Fidelity-affiliated global venture and growth investor with strong healthcare and biotech practice in Asia. Comparable to C-Bridge in Asia healthcare focus and proprietary deal flow, though predominantly growth-stage versus C-Bridge's M&A control orientation.
Regional players
- 3H Health Investment: China-dedicated healthcare buyout platform with a similar RMB-denominated fund structure and state-affiliated LP base. Comparable to C-Bridge in sector focus and capital sourcing, though typically operating at smaller fund sizes in the China domestic market.
Market position
Customer concentration
C-Bridge Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
C-Bridge Capital leadership team
Management profileNumber of profiles
Profiles4 records
C-Bridge Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
C-Bridge Capital M&A and investment
M&A and investmentM&A
Investments19 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about C-Bridge Capital
What does C-Bridge Capital do?
C-Bridge Capital is a healthcare-focused Chinese principal investment firm that raises and deploys capital through dedicated private equity vehicles, primarily the RMB Healthcare M&A Fund (target size 10 billion yuan, first close over 7 billion yuan). The fund is co-managed with Beijing Shunxi Fund and anchored by Beijing State-owned Assets Management Co., Ltd. and Beijing Yizhuang International Biomedical Investment Management Co., Ltd. The firm invests in and supports portfolio companies in the biopharmaceutical sector, including Everest Medicines and Hugel.
Is C-Bridge Capital a public or private company?
C-Bridge Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was C-Bridge Capital founded?
C-Bridge Capital was founded in 2022. It employs 101 to 250 people.
Where is C-Bridge Capital based?
C-Bridge Capital is headquartered in New York, United States, in the North America region.
How does C-Bridge Capital make money?
One revenue line is on record: fund Management.
Who are C-Bridge Capital's main competitors?
Direct peers on record are Hillhouse Capital, Boyu Capital, Vivo Capital, OrbiMed and Lakeside Capital (Lake Bleu Capital). Broad incumbents are Hopu Investments, Bain Capital Asia, Warburg Pincus and Eight Roads Ventures. 3H Health Investment is listed as a regional player.
Does C-Bridge Capital have an API?
No public API is recorded for C-Bridge Capital.
What industry is C-Bridge Capital in?
C-Bridge Capital's product category is Healthcare Private Equity. Its primary akta.pro industry code is FSANAGAD, Private Equity Buyout Fund-of-Funds, with a secondary code of BPAHADAB, Corporate Finance & Capital Advisory. Its NAICS code is 523940 and its SIC code is 6282.